Revvity (RVTY) said Monday it is launching Euroimmun's CE-marked anti-measles virus enzyme-linked immunosorbent assay 2.0, a test to diagnose measles infections or determine immunity.
The test is the first in a series that will expand Euroimmun's diagnostic portfolio, allowing the use of dried blood spots, or DBS, alongside serum and plasma. DBS testing requires only a small blood sample from a fingertip, making it easier and less invasive, especially in areas with limited medical infrastructure, the company said.
The test can be processed manually or automatically using Euroimmun's systems for DBS processing and enzyme-linked immunosorbent assay testing, Revvity said.
Price: 112.13, Change: -0.02, Percent Change: -0.02
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。